Есть много препаратов с нефротоксическим действием, это известно всем докторам, для этого делается элементарная вещь: мониторирования функции, это не сложно, рутинные биохимические исследования крови в помощь.
Могу заверить, что ни грандаксин, ни пирацетам, не отличились в таком "токси" эффекте, несмотря на многолетнюю(можно умножить на десятки лет) практику их использования.
- Форум Нейролептик.ру - консультации психиатра онлайн, отзывы о препаратах
- → Просмотр профиля: Репутация: versed
Статистика
- Группа: Врачи
- Сообщений: 57
- Просмотров: 8 900
- Статус: Частый гость
- Возраст: Неизвестен
- День рождения: Неизвестен
-
Пол
Мужчина
-
Город
Украина, Киевская область
-
Персональные данные
Инструменты
Последние посетители
#75207 Нефропротекторы
Написано versed на 19 Август 2013 - 07:42
#53876 Выход в свет практического пособия "Депрессии и резистентность"
Написано versed на 14 Август 2012 - 10:03
- 3
#22714 Прегабалин (Лирика)
Написано versed на 10 Январь 2010 - 03:22
Расшифровываю и сопоставляю: лирику использует весь мир, и не знает о таких проблемах которые Вы описываете. А коаксил не входит ни в одни рекомендации, соответственно очень ограниченно где используется - Коаксил, это пример почему не стоит использовать препараты в медицинской практике без должной доказательной базы. И даже терапевтические дозы этого вещества, зависимости не вызывают.
Никакого противоречия в своих словах не нахожу.
У Вас тогда явно мало практической деятельности, если такое говорите. О том как люди врут, и себе во вред, могу писать долго. Вы вроде наркологом работаете? Так в этой специальности такое явление наиболее выраженное, как способен врать наркоман знают и врачи и обыватели.Ну это вы "Доктора Хауза" пересмотрели явно
- "Все врут!"
Вот на чем я не основываю своем мнение, так это по опыту просмотренных сериалов, которых я не смотрю. Вам видней сюжет этой картины.
- 0
#22703 Прегабалин (Лирика)
Написано versed на 10 Январь 2010 - 02:12
И на основании этих сообщений хотите сделать выводы космического масштаба, что "на самом деле она существует"?Отчего же несуществующей?
Если вы хотя бы бегло просмотрите форум, то в разных разделах, разными пользователями не раз обсуждалась тема проблем после окончание приёма прегабалина.
Это личное мнение, которое совершенно не коррелирует с общепризнанным. Своими заявлениями идете наперекор мировому опыту и мнению, так может не стоит останавливаться в рамках этого форума в кармане с такой новостью? Вот сможете доказать, другое дело. Но уверен что не сможете. Принципы по которым живет современная медицина, должны Вам быть известны как врачу, вот пока очень жаль, что в наших странах их можно отвергать, и делать что душе угодно. Вот только больные от этого не выигрывают совершенно.
- -1
#22695 Прегабалин (Лирика)
Написано versed на 10 Январь 2010 - 12:57
- -3
#22566 Гипертоксическая шизофрения
Написано versed на 08 Январь 2010 - 11:41
И еще указано, что паранеопластичекий с-м, уже может возникать до клинически возможной верификации неоплазии.Около 40%, выходит, были не паранео- (или в очень ранней стадии?).
Но все таки 40% цифра не малая, брать во внимание стоит.
Я так понял данная патология характерна только для тератомы яичника, или для других новообразований тоже возможно ее развитие?
- -1
#22419 Гипертоксическая шизофрения
Написано versed на 07 Январь 2010 - 02:28
Joseph Tonkonogy, MD, PhD, Clinical Professor of Psychiatry and Neurology, University of Massachusetts Medical School; Consulting Staff, Departments of Psychiatry and Neurology, University of Massachusetts Medical Center
Darius P Sholevar, MD, Fellow, Cardiovascular Disease, Albert Einstein Medical Center
Updated: May 7, 2009
Introduction
Background
Neuroleptic malignant syndrome (NMS) refers to the combination of hyperthermia, rigidity, and autonomic dysregulation that can occur as a serious complication of the use of antipsychotic drugs. Delay first used the term in 1960, after observing patients treated with high-potency antipsychotics.[1 ]
Even the newer atypical antipsychotics, which are not classified accurately as neuroleptics, can cause neuroleptic malignant syndrome. Over the past 30 years, the syndrome has been associated with a variety of drugs that lead to decreased dopamine receptor activation.
While some clear risk factors for neuroleptic malignant syndrome are present, the low incidence of this syndrome and the consequent difficulty in studying it in a controlled, prospective manner make clinical features, predisposing conditions, treatment, and prognosis difficult to define.
Following is a case vignette of a patient with neuroleptic malignant syndrome that developed several days after the start of treatment with the atypical antipsychotic olanzapine.
A 66-year-old white male was hospitalized for increasingly aggressive behavior. He had no prior psychiatric admissions. On the day of admission after he sustained a fall, a CT scan of the brain revealed a subarachnoid hemorrhage at the right superior sulcus and a possible hemorrhagic contusion at the left frontal lobe. Over the course of hospitalization, the patient had a series of CT scans showing resolution of the hemorrhage. He was started on olanzapine for intermittent agitation. Olanzapine was titrated to 7.5 mg daily.
Ten days later the patient became abruptly somnolent with body temperature reaching 39.7 º C and severe muscle rigidity in both upper and lower extremities. He had severe diaphoresis and fluctuation of blood pressure and pulse. Laboratory data revealed elevation of white blood cells to 14800 K/L, creatine phosphokinase to 2800 U/L (normal <174 U/L), and mild elevation of serum alanine and aspartate aminotransferase. MRI of the brain, CSF studies, and chest radiograph were unremarkable. A presumptive diagnosis of neuroleptic malignant syndrome was made. Olanzapine was immediately discontinued and supportive care was initiated.
Intravenous lorazepam was given as needed every 4 hours for behavioral agitation along with a fixed 0.5 mg intravenous push twice daily. The patient received a total of 8.5 mg of lorazepam in the first 24 hours and 3 mg the next day. Fever and muscular rigidity resolved in 24 hours. All other manifestations of neuroleptic malignant syndrome resolved in 9 days.
Pathophysiology
The most widely accepted mechanism by which antipsychotics cause neuroleptic malignant syndrome is that of dopamine D2 receptor antagonism. In this widely accepted model, central D2 receptor blockade in the hypothalamus, nigrostriatal pathways, and spinal cord leads to increased muscle rigidity and tremor via extrapyramidal pathways. Hypothalamic D2 receptor blockade results in an elevated temperature set point and impairment of heat-dissipating mechanisms. Peripherally, antipsychotics lead to increased calcium release from the sarcoplasmic reticulum, resulting in increased contractility, which can contribute to hyperthermia, rigidity, and muscle cell breakdown.
Beyond these direct effects, D2 receptor blockade might cause neuroleptic malignant syndrome by removing tonic inhibition from the sympathetic nervous system. The resulting sympathoadrenal hyperactivity and dysregulation leads to autonomic dysfunction. This model suggests that patients with baseline high levels of sympathoadrenal activity might be at increased risk. While this has not been proven in controlled studies, several such states have been proposed as risk factors for neuroleptic malignant syndrome.[2 ]
Direct muscle toxicity also has been proposed as a mechanism of neuroleptic malignant syndrome.
Frequency
Neuroleptic malignant syndrome is associated with the use of various antipsychotic medicines, most frequently the older antipsychotics, termed neuroleptics. Development of neuroleptic malignant syndrome appears to be independent of the conditions that these medicines treat.
The syndrome can occur after any duration of treatment, although two thirds of cases occur within the first week. The frequency has been variably reported as 0.07–2.2% of patients taking neuroleptics.[3 ]Data largely come from case control studies rather than prospective randomized trials.
The frequency of neuroleptic malignant syndrome internationally parallels the use of antipsychotics, especially neuroleptics, in a given region. No data suggest geographic or racial variation. The one large randomized trial conducted in China showed an incidence of 0.12% in patients taking neuroleptics.[4 ]A retrospective study conducted in India showed an incidence of 0.14%.[5 ]
Mortality/Morbidity
Mortality from neuroleptic malignant syndrome is very difficult to quantify due both to the case report designs of most of the literature and to the inconsistency of the diagnostic parameters used.
• In some series, mortality rates as high as 76% have been reported. Most series suggest, however, that the mortality rate is 10-20%. When reporting bias is factored in, the true rate of mortality from neuroleptic malignant syndrome might be much lower.
• Studies have also found that the mortality rate has been decreasing over the past 2 decades. Mortality is generally higher in patients who develop severe muscle necrosis and resulting rhabdomyolysis.
Race
No data suggest geographic or racial variation.
Sex
Incidence is higher in males.
Age
• Incidence is higher in persons younger than 40 years. Differential incidence simply might reflect a population that has a high rate of antipsychotic usage.
• Some small case series looking at neuroleptic malignant syndrome in elderly patients suggest that onset might occur after a longer duration of antipsychotic use.
• Studies in children suggest that clinical presentation might be somewhat different.
Clinical
History
• Criteria for the diagnosis of neuroleptic malignant syndrome are based on clinical features. Cardinal features are the development of severe muscular rigidity, hyperthermia, autonomic instability, and changes in the level of consciousness associated with the use of an antipsychotic medication, most often a neuroleptic.
• In addition to hyperthermia and rigidity, at least 2 other clinical features of neuroleptic malignant syndrome, including leukocytosis and laboratory evidence of muscle injury, should be present.
• The key to diagnosis is that symptoms occur only after exposure to antipsychotics. Symptoms should improve after the antipsychotic is stopped. No new focal neurological deficits should develop, although cases of neurological sequelae have been reported rarely.
• A summary of the clinical features of neuroleptic malignant syndrome includes the following:
o Diaphoresis
o Dysphagia
o Tremor
o Incontinence
o Delirium progressing to lethargy, stupor, coma
• Labile blood pressure
• Pallor
• Dyspnea
• Psychomotor agitation
• Rigidity
• Hyperthermia
• Tachycardia
• Shuffling gait
• For accurate diagnosis, rule out reaction to another medication or medical condition that might be a more likely cause of the symptoms than use of an antipsychotic.
• Various other medications cause conditions that are indistinguishable from neuroleptic malignant syndrome and likely involve similar chemical structure and the same pathophysiology. All of these agents, including metoclopramide, prochlorperazine, promethazine, and droperidol, cause decreased dopamine receptor activation.
• A similar syndrome also has been associated with the rapid removal of medications with dopaminergic properties (eg, in patients treated for Parkinson disease).[6 ]Medications in these classes often are used to treat Parkinson disease and include levodopa, bromocriptine, and amantadine. Dopaminergic drugs should be started as soon as possible to prevent rhabdomyolysis and renal failure.[7 ]
• Lethal catatonia (LC) is a similar condition that might be confused with neuroleptic malignant syndrome. Lethal catatonia occurs in people with schizophrenia or during manic episodes. Neuroleptics might either improve or worsen the symptoms of lethal catatonia. Distinguishing lethal catatonia from neuroleptic malignant syndrome can be difficult, although a detailed history might reveal episodes of catatonia while a patient is not taking neuroleptics. Lethal catatonia also tends to have a prodrome of excitement and agitation prior to the onset of rigidity, while neuroleptic malignant syndrome tends to begin with rigidity.[8 ]
• Antipsychotics can cause a variety of reactions that can be confused with neuroleptic malignant syndrome. These reactions often occur with increasing medication dosages. Neuroleptic-induced acute dystonia is an abnormal contraction or spasm of a group of skeletal muscles, often involving the head or neck. Neuroleptic-induced acute akathisia is motor restlessness, particularly involving the legs. Neuroleptic-induced tardive dyskinesia involves involuntary, rhythmic movements starting with mouth movements. Neuroleptic-induced parkinsonism, or pseudoparkinsonism, presents with the classic triad of tremor, muscular rigidity, and akinesia. Despite the term neuroleptic-induced, these conditions also can be caused, although less frequently, by many of the newer, nontraditional antipsychotic medications as well. In future editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM), the terminology might be changed to include nonneuroleptic antipsychotics.
• The serotonin syndrome is very similar to neuroleptic malignant syndrome. The triad of (1) altered mental status, (2) autonomic dysfunction, and (3) neuromuscular abnormalities that occurs on exposure to serotonergic agents characterizes the serotonin syndrome. Selective serotonin reuptake inhibitors (SSRIs) are the most frequently used medications in this class. The proposed mechanism is excessive 5-hydroxytryptamine (5-HT or serotonin) stimulation. Given the increasing use of the SSRIs, the serotonin syndrome might become increasingly prevalent. The serotonin syndrome can be distinguished from neuroleptic malignant syndrome in most cases by a detailed history of medication use with particular attention to recent dosage changes and the absence of severe rigidity. Treatment of this condition includes removal of the offending drug and supportive management, though 5-HT1A antagonists might have a role in the future.[9,10 ]
• Medication-induced movement disorders not otherwise specified can be very similar to neuroleptic malignant syndrome but occur on exposure to other psychotropic medications. Malignant hyperthermia (MH) occurs after administration of halogenated inhalational anesthetics, such as halothane, and depolarizing muscle relaxants, such as succinylcholine, to genetically susceptible individuals. An underlying defect is an autosomal dominant mutation in the ryanodine receptor, which leads to excessive calcium release from the sarcoplasmic reticulum in skeletal muscle when one of the above agents is administered. A multifactorial pattern of inheritance also has been postulated. Malignant hyperthermia can be distinguished readily by history. Treatment is based on supportive care, use of dantrolene to decrease calcium release, and avoidance of precipitating medications. No evidence shows that neuroleptic malignant syndrome occurs more frequently in patients susceptible to malignant hyperthermia.
• Heat stroke can cause a similar picture, but patients have dry skin and flaccidity in addition to hyperthermia and hypotension.
• General medical conditions that might mimic neuroleptic malignant syndrome include central nervous system infections, status epilepticus, stroke, brain trauma, neoplasms, acute intermittent porphyria, and tetanus.
• Laboratory abnormalities observed in neuroleptic malignant syndrome have broad differential diagnoses and only specific points are presented in this chapter (see Lab Studies). Elevated creatine kinase (CK) can be observed with intramuscular injections and the use of restraints. Leukocytosis occurs with central nervous system infections.
Physical
Neuroleptic malignant syndrome tends to start with muscular rigidity and progress to hyperthermia with autonomic instability and a fluctuating level of consciousness. Compared to disease in adults, neuroleptic malignant syndrome in children and adolescents tends to present with more dystonia and less tremor.
• Symptoms of autonomic dysregulation include high fever, diaphoresis, tachypnea, tachycardia, and increased or labile blood pressure. In rare cases, a reversible cardiomyopathy mimicking cardiac infarction may develop the autonomic involvement in the course of neuroleptic malignant syndrome.[11 ]
• Extrapyramidal symptoms include so-called lead pipe rigidity; dysphagia; a short, shuffling gait; resting tremor; dystonia; and dyskinesia.
• Excessive or purposeless motor activity and tremor can reflect psychomotor agitation.
• Delirium is characterized by the following:
o Loss of awareness
o Detachment from both the inside and outside worlds
o Loss of orientation in time and space
o Reduced ability to sustain the attention that wanders around and can not be directed at will
o Speech that is often mumbled and incoherent
o Development of illusions and hallucinations, especially visual
o Level of consciousness fluctuates but may eventually decrease to the stages of lethargy, stupor, or coma
• Other features include pallor, rash, and dyspnea.
Causes
All classes of antipsychotics have been associated with neuroleptic malignant syndrome, including low-potency neuroleptics, high-potency neuroleptics, and the newer (or atypical) antipsychotics. Neuroleptic malignant syndrome has been reported most frequently in patients taking haloperidol and chlorpromazine.
• The clearest risk factors relate to the time course of therapy. Strongly associated factors are the use of high doses of antipsychotics (particularly the high-potency neuroleptics), rapid antipsychotic dosage increases, and the use of depot, the long-acting injectable forms of antipsychotics.[12 ]In the United States, only 3 long-acting forms are available at present—fluphenazine decanoate or enanthate, haloperidol decanoate, and risperdal consta.
• Other factors related to a patient's pharmacotherapy might be relevant, although their role has not been proven in controlled studies. Inconsistent use of neuroleptics and the use of other psychotropic medications, particularly lithium, have been suggested as risk factors. Prior treatment with electroconvulsive therapy (ECT) also has been proposed to have a role.
• Environmental and psychological factors that might predispose to neuroleptic malignant syndrome are hot and humid conditions, agitation, dehydration, and exhaustion.
• A number of demographic features have been implicated, many of which simply might reflect populations that have a high rate of neuroleptic usage. These include male sex and age younger than 40 years. Neuroleptic malignant syndrome has been reported in postpartum women.
• Genetic factors also might play a role. Case reports have been published on neuroleptic malignant syndrome occurring in identical twins as well as in a mother and 2 of her daughters[13 ].
• Patients who have experienced episodes of neuroleptic malignant syndrome previously are at risk for recurrences. The risk of recurrence is strongly related to the elapsed time between an episode of neuroleptic malignant syndrome and restarting antipsychotics.
o If patients are rechallenged with antipsychotics within 2 weeks of an episode of neuroleptic malignant syndrome, 63% will have a recurrence. If more than 2 weeks have elapsed, only 30% will have a recurrence.
o Eighty-seven percent of patients who develop neuroleptic malignant syndrome will be able to tolerate an antipsychotic at some point in the future. Given the present understanding of this syndrome, on reintroducing an antipsychotic, switch to a different antipsychotic class and, if possible, use an atypical antipsychotic because these might be less likely than traditional neuroleptics to cause neuroleptic malignant syndrome.
• A summary of medications that may induce movement disorders includes the following:
o MAOIs
o MAOIs combined with tricyclic antidepressants
o MAOIs combined with serotonergic agents
o MAOIs combined with meperidine
o Lithium at toxic levels
o Anticholinergics
o Amphetamines
o Fenfluramine
o Cocaine
o Phencyclidine
o 3,4-Methylenedioxymethamphetamine (MDMA; ecstasy, XTC)
o Methylphenidate[14 ]
• A summary of the well supported risk factors for neuroleptic malignant syndrome includes the following:
o High-potency neuroleptic use
o High-dose neuroleptic use
o Rapid increase in neuroleptic dose
o Depot injectable neuroleptic use
o Prior episodes of neuroleptic malignant syndrome
o Age younger than 40 years
o Male sex
• A summary of the potential risk factors for neuroleptic malignant syndrome includes the following:
o Dehydration[15 ]
o Agitation[15 ]
o Exhaustion
o Malnutrition
o Organic brain syndromes
o Nonschizophrenic mental illness
o Lithium use
o Past history of electroconvulsive therapy
o Warm and humid environments
o Inconsistent use of neuroleptics
o Postpartum period[16 ]
Differential Diagnoses
Schizophrenia
Other Problems to Be Considered
Manic-depressive illness, Lethal catatonia, Neuroleptic-induced acute dystonia, Neuroleptic-induced acute akathisia, Neuroleptic-induced tardive dyskinesia, Neuroleptic-induced parkinsonism, Serotonin syndrome, Malignant hyperthermia, Heat stroke, Central nervous system infections, Status epilepticus, Stroke, Brain trauma, Neoplasms, Acute intermittent porphyria, Tetanus.
Workup
Laboratory Studies
• The rigidity and hyperthermia found in neuroleptic malignant syndrome contribute to muscle damage and necrosis. Elevated blood CK, aminotransferases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]), and lactate dehydrogenase (LDH) reflect damage and necrosis, which can progress quickly to rhabdomyolysis with hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. Elevated blood levels of myoglobin and myoglobinuria can be observed and ultimately can lead to renal failure.
• More general laboratory features include leukocytosis, thrombocytosis, and evidence of dehydration. Cerebrospinal fluid protein might be elevated. Serum iron concentration might be decreased.
• Investigate other causes for fever based on the clinical scenario.
• Investigate symptoms and signs of urinary tract, respiratory, and CNS infections.
• A summary of the laboratory abnormalities associated with neuroleptic malignant syndrome includes the following:
o Increased LDH
o Increased CK
o Increased AST
o Increased ALT
o Increased alkaline phosphatase
o Hyperuricemia
o Hyperphosphatemia
o Myoglobinemia
o Leukocytosis
o Thrombocytosis
o Proteinuria
o Decreased serum iron[18 ]
o Increased cerebrospinal fluid (CSF) protein
o Hypocalcemia
o Myoglobinuria
Treatment
Medical Care
The most important intervention is to discontinue all antipsychotics. In most cases, symptoms will resolve in 1-2 weeks. Neuroleptic malignant syndrome precipitated by long-acting depot injections of antipsychotics can last as long as a month. During the course of neuroleptic malignant syndrome, use supportive care aggressively. The value of other interventions, such as dantrolene, amantadine, bromocriptine, and electroconvulsive therapy, is uncertain.[19 ]
• Supportive measures are aimed at preventing further complications and maintaining organ function.
o Patients should receive circulatory and ventilatory support as needed.
o Cooling blankets and antipyretics can be used to control temperature.
o Aggressive fluid resuscitation and alkalization of urine can help prevent acute renal failure and enhance excretion of muscle breakdown products.
• Electroconvulsive therapy has been proposed as a treatment based on its effectiveness in acute lethal catatonia. Some data suggest that electroconvulsive therapy is effective for neuroleptic malignant syndrome, but serious treatment-related complications have occurred (see Complications). Specifically, patients with neuroleptic malignant syndrome have developed cardiac arrest and ventricular fibrillation after electroconvulsive therapy.
Medication
Specific drug therapies, such as dantrolene, amantadine, bromocriptine, and electroconvulsive therapy, have an uncertain role in the treatment of neuroleptic malignant syndrome. While they generally are felt to be helpful, they have been found to be deleterious in some studies.
Benzodiazepines, used in a small number of patients unresponsive to above measures. In most cases, a continuous IV infusion of diazepam or lorazepam has been utilized.
Follow-up
Complications
• Complications of neuroleptic malignant syndrome include dehydration from poor oral intake, acute renal failure from rhabdomyolysis, and deep vein thrombosis and pulmonary embolism from rigidity and immobilization.
• Avoiding antipsychotics can cause complications related to uncontrolled psychosis. Most patients taking antipsychotic medicines are being treated for a severe and persistent psychiatric disorder; a high likelihood exists that a patient will relapse while off antipsychotics.
• A summary of the potential complications of neuroleptic malignant syndrome includes the following:
o Rhabdomyolysis
o Renal failure
o Cardiac arrest
o Infection
o Aspiration
o Respiratory failure
o Seizure
o Pulmonary embolism
o Hepatic failure
o Uncontrolled psychoses
Prognosis
• Most series suggest that the mortality rate is 10-20%. When reporting bias is factored in, the true rate of mortality from neuroleptic malignant syndrome might be much lower. Mortality rates generally are higher in patients who develop severe muscle necrosis and resulting rhabdomyolysis.
• Patients who have previously experienced episodes of neuroleptic malignant syndrome are at risk for recurrences. The risk of neuroleptic malignant syndrome recurrence is strongly related to the elapsed time between an episode of neuroleptic malignant syndrome and restarting antipsychotics.
o If patients are rechallenged with antipsychotics within 2 weeks of an episode of neuroleptic malignant syndrome, 63% will have a recurrence. If more than 2 weeks has elapsed, only 30% will have a recurrence.
o Eighty-seven percent of patients who develop neuroleptic malignant syndrome will be able to tolerate another antipsychotic at some point in the future, which is very important because most patients taking neuroleptics require them to maintain a reasonable functional status. Current practice is to switch to a different class of antipsychotic when reintroducing these medications. Often, one of the newer atypical antipsychotics is chosen because current evidence suggests a lower incidence of neuroleptic malignant syndrome with these agents.
Patient Education
• Educational approaches can help patients and their relatives to understand what has happened to the patient, why the neuroleptic malignant syndrome has developed in the past, and what possibility of the recurrence of neuroleptic malignant syndrome if the patient is rechallenged with a different class of antipsychotics. This may help patients and their relatives to decide about giving consent to restart antipsychotics. They have to be aware of the early signs of developing neuroleptic malignant syndrome such as rigidity, hyperthermia, and changes of consciousness to bring attention of the medical staff to the possible redevelopment of neuroleptic malignant syndrome.
• Helpful Web sites for patients include the following:
o Neuroleptic Malignant Syndrome Information Service
o NINDS Neuroleptic Malignant Syndrome Information Page
o WebMD, Neuroleptic Malignant Syndrome
- 1
#21945 Циннаризин
Написано versed на 29 Декабрь 2009 - 01:44
Понятие "силы препарата" сугубо обывательское, в природе такого не существует. По чем оценивать ту самую "силу"? По наличию и частоте побочных эффектов, или эффективности препарата при патологиях, или может по красивой упаковке и отзывам соседей?судя по цене препарат не сильный и(как выяснилось) без каких либо выраженных побочных действий.Покопался внимательнее в интернете и нашел,что его и детям и пожилым людям прописывают,из чего можно сделать что препарат нельзя отнести к разряду очень сильных,не так ли?
Вот что точно, не определяет эффект лекарств, так это цена.
- 1
#21839 Мексидол
Написано versed на 28 Декабрь 2009 - 12:46
короче говоря лекарство от всех болезней просто,даже читать смешно.
Если верить инструкции, им стоило бы поливать кладбищенские земли, он такой целительный, что мертвые должны вставать
- 1
#21745 Пипофезин (Азафен)
Написано versed на 27 Декабрь 2009 - 02:25
Если у человека с депрессией случается инфаркт миокарда(ИМ), то тут приоритет резко сдвигается в строну терапии ИМ, и это понятно почему: от этой патологии умирают, это состояние вызывает шок, тяжелые нарушение состояния. И все терапевтические мероприятия направлены на восстановления кровотока в миокарде/ограничению зоны ишемии и некроза и тд...Про депрессию можно грубо говоря забыть, на некоторое время, а вот а период реабилитации "вспомнить", когда уже будет контроль над ситуацией.Действительно интересно versed , а какова тактика лечения тяжелых депрессий при инфакрке миокарда ?
И еще вот, ИМ длится не всю жизнь, а 28 дней со дня события.
В принципе, психические расстройства в людей когда они попадают в реанимацию, случаются сплошь и рядом. Есть даже термин: "Психоз отделения интенсивной терапии". Этому способствует куча причин, но это все временно и проходит С чем наиболее всего часто приходится сталкиваться, это возбуждение, делирий, ажитация. И терапия соответственно симптоматическая: седация, плюс устранение причин, насколько это возможно, которые могли вызвать расстройство, и профилактика само-собой.
- 0
#21740 Пипофезин (Азафен)
Написано versed на 27 Декабрь 2009 - 01:54
Все намного меньше и проще будет казаться, если ситуацию будет оценивать врач. Я вот представил, как человек не имеющий мед.образования, прочитает классификацию ИБС а там первый пункт "внезапная сердечная смерть", а как поглядеть дальше..., для его это будет набор страшных фраз, и сразу в голове куча ненужных ассоциаций и мыслей. Ситуацию должен оценивать специалист, обыватель это не в состоянии сделать, Я вот мосты не рвусь почему то строить(не мое это дело), а в медицине все хотят показать что они разбираются, потому куча мифов и шарлатанов.а вот именно под "ишемией" подразумевается такая огромная группа заболеваний......
- 0
#21697 Пипофезин (Азафен)
Написано versed на 27 Декабрь 2009 - 12:46
"Болезни сердца" их ох как много, и объединять все как одно противопоказание, есть не правильно.Подскажите пожалуйста, почему мелипрамин, анафранил нельзя при болезнях сердца (противопоказаны при всех), а азафен разрешен к применению, только с осторожностью при ИБС и инфаркте. Ведь тоже трициклик.
Всегда смешили такие фразы в инструкциях к препаратам как : "Применять с осторожностью..." , это как, в одну руку берем таблетку азафена и осторожно кладем в рот, одновременно в другой руке затаив нитроглицерин?
Для всех препаратов есть показания/противопоказания и пункт "особенности применения" который объясняет риски и как их избежать с подробным описанием, что в отечественных инструкциях благополучно заменили на общую ничего не несущую фразу под собой как "применять с осторожностью".
- -1
#16535 Афобазол
Написано versed на 29 Июль 2009 - 03:09
Плохо, что только я поднимаю проблемы наркологии, ну а беседовать лично с врачом, который не умеет работать с препаратом, оскорбляет сперва сам, а потом просит, чтоб его персону не оскорбляли - нет желания. А знак молчания с моей стороны относительно ТОГО ВОПРОСА ВАШЕГО - это обычно и дебилы(медицинское) понимают, поэтому извольте.
Ответ такого уровня достойный персоны с более глубокой степенью олигофрении, чем дебилизм. Поскольку так и ускользаете от ответа на прямо поставленные вопросы, прихожу к выводу, вы просто на это неспособны, а лишь только передергиваете дискуссию.
- -2
#16484 Афобазол
Написано versed на 27 Июль 2009 - 12:46
Вы вообще ходили по представленным ссылкам-мексидол? Первая англ.перевод отечественных сомнительных работ, вторая ничего общего не имеет с людьми. Как это понимать? Неуважение к оппоненту? Остальные ссылки представлены отечественными работами в духе: использовано в 50-ти человек, высокоэффективный в 95%, 5% малоэффективный с последующим призывом широкого использования вещества.
У меня довольно огромный опыт введения больных с алкогольными психозами, так введение их по цивилизованным рекомендациям увеличивает шансы выжить, и укротить период психоза. На моей практике, что только не использовали с "метаболических препаратов", и толку ноль, мало того можно получить аллергические реакции. Как только начали работать по европейским стандартам, показатели поползли вверх. И это не по наслышке, я дипломированный анестезиолог-реаниматолог, и верю только фактам, эмоции и личные впечатления губительны в отношении человеческих жизней . Я вот задумался может и анестезии мексидолом проводить, авось фентанила не надо будет вводить?
С какой целью Вы меня обозвали "умным", и за меня позволили себе выразится что я считаю всех дураками?
Вы так и не ответили на вопрос: Вы врач? Если да, хотелось бы поговорить лично, надеюсь наберетесь смелости
Для чего было писать такую груду информации, с которой не возможно вынести хоть что-то толковое, аккуратно залепив поле названиями других веществ, дозами, эффектами(сомнительными), формулами. Надеетесь чем больше пост, тем "круче", я на такое не ведусь.
Мои выводы подкреплены исключительно на доказательствах. Я не знаю что бы где то фигурировали названные Вами "Антиоксиданты" в европейских или американских рекомендация. Тем более что бы где нибудь в мире кроме стран СНД применялся мексидол и иже с ним, может подскажете? Эффективность антиоксидантов тоже давно уже НЕ доказана. Для витаминчиков тоже есть узкие показания, и они известны, есть четкая позиция что давать их всем кто ходит на прием к врачу даже вредно, к примеру ретинол повышает смертность у больных с ИБС на 6%.
Предлагаю вести диалог по сути, без оскорблений и ярких эмоций. Если Вы не признаете традиционную медицину, построенную на доказательствах- это ставит под сомнение Вашу квалификацию.
- -3
- Форум Нейролептик.ру - консультации психиатра онлайн, отзывы о препаратах
- → Просмотр профиля: Репутация: versed
- Соглашение на обработку персональных данных
- Правила форума ·